I7G.F Ipsen S.A

Healthcare Pharmaceuticals Frankfurt Exchange
167.20 EUR
Close of Nov 12, 2026
114.98 172.30
Market cap
EUR 13.8B
P/E
27.1x
P/B
2.90x
ROE
10.2%
Dividend yield
0.84%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is I7G.F undervalued?

Graham number
Price167.20
Graham value89.57
Premium86.7%

I7G.F trades 86.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ipsen S.A fundamental analysis

No fundamental analysis for Ipsen S.A yet.

Ipsen S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ipsen S.A

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, fema…

Full company profile